Eli Lilly and Co 2024 SR
The report highlights Eli Lilly's progress toward its 2030 sustainability goals, including a 37% reduction in Scope 1 and 2 emissions since 2020 and securing 58% of purchased electricity from renewable sources. The company reached 58 million people with its medicines in 2024, including 24 million in resource-limited settings as part of its Lilly 30x30 initiative. Significant efforts were made in waste management, with 1.1% of routine operational waste sent to landfills and 95.7% of plastic waste repurposed. The report also details the launch of LillyDirect to improve patient access and affordability in the U.S.
Company: Eli Lilly and Co
Sector: Health Care
Country: United States
Year: 2024
Type: SR
Pages: 100
Eli Lilly and Co
Sustainability Report
The report highlights Eli Lilly's progress toward its 2030 sustainability goals, including a 37% reduction in Scope 1 and 2 emissions since 2020 and securing 58% of purchased electricity from renewable sources. The company reached 58 million people with its medicines in 2024, including 24 million in resource-limited settings as part of its Lilly 30x30 initiative. Significant efforts were made in waste management, with 1.1% of routine operational waste sent to landfills and 95.7% of plastic waste repurposed. The report also details the launch of LillyDirect to improve patient access and affordability in the U.S.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Jun 6, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Workplace Fatalities